Are estrogens carcinogens?;Sind estrogene karzinogene?

Zentralblatt fur Gynakologie

Volumn 124, Issue 12, 2002, Pages 559-565

  Emons, Günter ^a   Grundker C ^a   Hanf, V ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

4 Hydroxyestrogens; Carcinogenesis; Catecholestrogens; Estrogens

Indexed keywords

4 HYDROXYESTROGEN DERIVATIVE; CATECHOL ESTROGEN; CYTOCHROME P450 1A; CYTOCHROME P450 1B1; CYTOCHROME P450 3A; ESTRADIOL; ESTROGEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER RISK; CARCINOGENIC ACTIVITY; DNA DAMAGE; ENDOMETRIUM CANCER; ESTROGEN METABOLISM; HUMAN; MUTAGENESIS; OVARY CANCER; REVIEW; RISK ASSESSMENT;

BREAST NEOPLASMS; CARCINOGENS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ESTROGEN;

EID: 0038479979     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-40168     Document Type: Review

References (36)

1. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in Combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 355: 2131-2139
2. Chen Y, Liu X, Pisha E, Constantinou AI, Hua Y, Shen L, van Breemen RB, Elguindi EC, Blond SY, Zhang F, Bolton JL. A metabolite of equine estrogens, 4 hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol 2000; 13: 342-350
3. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in human breast. Cancer Res 1997; 57: 4987-4991
4. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy and breast cancer. J Natl Cancer Inst 1998; 90: 814-823
5. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047-1059
6. Emons G, Hoppen HO, Ball P, Knuppen R. 4-Hydroxyestrone, isolation and identification in human urine. Steroids 1980; 36: 73-79
7. Emons G, Mente C, Knuppen R, Ball P. Radioimmunoassay of 4-hydroxyestrone in human urine. Acta Endocrinol (Copenh.) 1981: 97: 251-257
8. Emons G, Ball P, Knuppen R. Radioimmunoassays of catechol estrogens. In: Merriam GR, Lipsett MB (Hrsg): Catecholestrogens, Raven Press, New York 1983; 71-83
9. Emons G, Merriam GR, Pfeiffer D, Loriaux DL, Ball P, Knuppen R. Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male. J Steroid Biochem 1987; 28: 499-504
10. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocrine Related Cancer 2000; 7: 227-242
11. Fotsis T, Zhang Y, Pepper M, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 1994; 368: 237-239
12. Goodman MT, McDuffle K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, Guo C, Le Marchand L. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidem Biomarkers Prevention 2001; 10: 209-216
13. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-433
14. Hiraku Y, Yamashita N, Nishiguchi M, Kawanishi S. Catechol estrogens induce oxidative DNA damage and estradiol enhances cell proliferation. Int J Cancer 2001; 92: 333-337
15. International Agency for Research on Cancer. Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC, Lyon, Frankreich 1987; Suppl 7: 280-285
16. International Agency for Research on Cancer. Monographs on the Evaluation of Carcinogenic Risks to Humans: Hormonal Contraception and Postmenopausal Hormone Therapy. IARC, Lyon, Frankreich 1999; 72: 474-530
17. Jefcoate CR, Liehr JG. Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G, Berstein L. Tissue-specific synthesis and oxidative metabolism of estrogens. J National Cancer Inst Monogr 2000; 27: 95-112
18. Kuhl H. Sind Estrogene Karzinogene? J Menopause 2002; 2: 19-28
19. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288: 334-341
20. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocrine Reviews 2000; 21: 40-54
21. Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanisms of uterine and mammary cancer development. Human Reproduction Update 2001; 7: 273-281
22. Mottram DS, Wedzicha BL, Dodson AT. Acrylamide is formed in the Maillard reaction. Nature 2002; 419: 448-449
23. National Toxicology Program. National Institute of Environmental Health Sciences. Report on Carcinogens 2000 http://www.niehs.nih.gov/news/rocrslt.htm
24. Reid SE, Murthy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. British Journal of Surgery 1996; 83: 1037-1041
25. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR. Hormone replacement therapy and risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94: 497-504
26. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 1460-1465
27. Russo J, Hu YF, Yang X, Russo JH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Mongr 2000; 27: 17-37
28. Russo J, Lareef MH, Tahin Q, Hu YF, Slater C, Ao X, Russo IH. 17 Beta-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 2002; 80: 149-162
29. Santen RJ. To block estrogen's synthesis or action: that is the question. J Clin Endocrinol Metab 2002; 87: 3007-3012
30. Stadler RH, Blank I, Varga N, Robert F, Hau J, Guy PA, Robert MC, Riediker S. Acrylamide from Maillard reaction products. Nature 2002; 419: 449-450
31. Thompson PA, Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 2000; 27: 125-134
32. Todorovic R, Devanesan P, Higginbotham S, Zhao J, Gross MR, Rogan EG, Cavalieri EL. Analysis of potential biomarkers of estrogen-initiated cancer in the urine of Syrian golden hamsters treated with 4-hydroxyestradiol. Carcinogenesis 2001; 22: 905-911
33. Tsutsui T, Barrett JC. Neoplastic transformation of cultured mammalian cells by estrogens and estrogenlike chemicals. Environ Health Perspect 1997; 105 (Suppl 3): 619-624
34. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002; 288: 321-333
35. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000; 27: 67-73
36. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58: 2269-2277